Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Neoplasms 2Urologic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Adenoid Cystic 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 329Cisplatin 276Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 210Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Has results × GSK-3326595 × Clear all
NCT02783300 2025-03-10

Meteor 1

GlaxoSmithKline

Phase 1 Completed
297 enrolled 76 charts
DermatologicGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Lymphoma, Non-Hodgkin, Melanoma, Neoplasms, Urologic Neoplasms

NCT03614728 2023-02-06

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

GlaxoSmithKline

Phase 1/2 Terminated
30 enrolled 29 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡